Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Brentuximab Associated Guillain-Barré Syndrome (BV-GBS): Case Series and a Review of Pharmacovigilance FDA Adverse Reporting System (FAERS)

Roshini Pradeep, Zeynep Nazli Benekli, Ranjit Nair, Luis Malpica, Hun Ju Lee, Eguono Maples, Samantha Carlson, Luis E. Fayad, Sairah Ahmed, Swami P. Iyer

Blood (2024) 144 (Supplement 1): 7776.

https://doi.org/10.1182/blood-2024-202119

Published: 2024

Journal Articles

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2024-206042

Published: 2024

Journal Articles

Trial in Progress: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-Cop to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma - Crescendo

Yun Kyoung Tiger, Uma Atmuri, Swami P. Iyer

Blood (2024) 144 (Supplement 1): 3123.1.

https://doi.org/10.1182/blood-2024-197991

Published: 2024

Journal Articles

An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL

Ranjit Nair, Daniela E. Duenas, Jingjing Liu, Rishab Prakash, Chen Zhou, Ayse A Koksoy, Jie Xu, Salome A McAllen, Luis Malpica, Raja Luthra, Francisco Vega, Roberto N. Miranda, Jianhua Zhang, L. Jeffrey Medeiros, Cara L Haymaker, Christopher R. Flowers, Sattva S. Neelapu, Swami P. Iyer

Blood (2024) 144 (Supplement 1): 455.

https://doi.org/10.1182/blood-2024-211900

Published: 2024

Journal Articles

Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Preetesh Jain, Hun Ju Lee, Jason Westin, Loretta J. Nastoupil, Luis Fayad, Ranjit Nair, Swami P. Iyer, Rashmi Kanagal-Shamanna, Ahmed Fetooh, Holly A Hill, Chi Young Ok, Wendy Chen, Onyeka Oriabure, Lei Feng, Guilin Tang, Francisco Vega, Maria Badillo, Christopher R. Flowers, Michael L. Wang

Blood (2023) 142 (Supplement 1): 1688.

https://doi.org/10.1182/blood-2023-181312

Published: 2023

Journal Articles

Preclinical Evaluation of T-Cell Prolymphocytic Leukemia Demonstrates Heterogeneous BCL2-Family Dependency That May be Effectively Targeted with Small Molecule Inhibitors

Vishakha Anand Pawar, Akanksha Aradhya, Daniel Galvan, Gautam Borthakur, Swami P. Iyer, Mark Kirschbaum, David Blake, Tapan M. Kadia, Deepa Sampath, Francisco Vega

Blood (2023) 142 (Supplement 1): 4192.

https://doi.org/10.1182/blood-2023-178256

Published: 2023

Journal Articles

Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 856.

https://doi.org/10.1182/blood-2023-180381

Published: 2023

Journal Articles

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Blood (2023) 142 (Supplement 1): 2537.

https://doi.org/10.1182/blood-2023-188829

Published: 2023

Journal Articles

Developing Deep Learning Pipeline of Whole-Slide Images for Enhanced Diffuse Large B Cell Lymphoma (DLBCL) Subtyping and Outcome Prediction: Leveraging Self-Attention Transformer for Training and Inference

Chen Zhou, Jie Xu, Rishab Prakash, Carlos P Torres-Cabala, Cheng-bang Chen, Kamesh Madduri, Arvind Rao, Greeshma Agasthya, Francisco Vega, Dennis O'Malley, L. Jeffrey Medeiros, Soundar Kumara, Swami P. Iyer

Blood (2023) 142 (Supplement 1): 904.

https://doi.org/10.1182/blood-2023-187291

Published: 2023

Journal Articles

Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial

Blood (2023) 142 (Supplement 1): 3036.

https://doi.org/10.1182/blood-2023-181216

Published: 2023

Journal Articles

Differing Inflammatory Profiles and Survival Outcomes of Cytokine Storm Arising from CAR T-Cell Therapy, COVID and Malignancy-Associated HLH in Patients with Hematological Malignancies

Blood (2023) 142 (Supplement 1): 3507.

https://doi.org/10.1182/blood-2023-187946

Published: 2023

Journal Articles

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

Hans C. Lee, June Li, Heather Lin, Astrid D. Murga, Gabriela M Rodriguez, Mostafa E. Mohamed, Jared Henderson, Sarah Rodriguez, Melody R. Becnel, Donna M. Weber, Swami P. Iyer, Gregory P. Kaufman, Sheeba K. Thomas, Elisabet E. Manasanch, Krina K. Patel, Stephen J. Noga, Michael R. Green, Robert Z. Orlowski, Cara L Haymaker

Blood (2023) 142 (Supplement 1): 4760.

https://doi.org/10.1182/blood-2023-188201

Published: 2023

Journal Articles

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS): A Review of Pharmacovigilance

Ugochi Ebinama, Rishab Prakash, Paolo Strati, Sairah Ahmed, Sherry Adkins, Samer A. Srour, Michael L. Wang, Preetesh Jain, Elizabeth J. Shpall, Anath Lionel, Meng Lui, Sattva S. Neelapu, Krina K. Patel, Swami P. Iyer

Blood (2023) 142 (Supplement 1): 5132.

https://doi.org/10.1182/blood-2023-185190

Published: 2023

Journal Articles

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

Swami P. Iyer, Sabarish R. Ayyappan, Irl Brian Greenwell, Won Seog Kim, Seung Tae Lee, Jin Seok Kim, Won-Sik Lee, Youngwoo Jeon, William Johnson, Utpal P. Dave, Sung-Soo Yoon, Ka-Won Kang, Florent Carrette, Julien Viotti, A.J. Leyco, Marianna Muller, Steven M. Horwitz

Blood (2023) 142 (Supplement 1): 3072.

https://doi.org/10.1182/blood-2023-172537

Published: 2023

Journal Articles

Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2023-187903

Published: 2023

Journal Articles

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Blood (2023) 142 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2023-184933

Published: 2023

Journal Articles

Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma

Alexandra Elias, Mario L. Marques-Piubelli, Ranjit Nair, Rishab Prakash, Sairah Ahmed, Luis Malpica, Hun Ju Lee, Jie Xu, Christopher R. Flowers, Sattva S. Neelapu, Francisco Vega, Roberto Miranda, Swami P. Iyer

Blood (2023) 142 (Supplement 1): 1714.

https://doi.org/10.1182/blood-2023-187939

Published: 2023

Journal Articles

Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma

Jason Westin, Ranjit Nair, Luis Fayad, Swami P. Iyer, Luis Malpica, Sattva S. Neelapu, Felipe Samaniego, Raphael Eric Steiner, Paolo Strati, Shivon Mathew, Donna Griffith, Loretta J. Nastoupil, Wirt Montinez, Maria Alma Rodriguez, Frederick Hagemeister, Lei Feng, Francisco Vega, Christopher R. Flowers, Sairah Ahmed

Blood (2023) 142 (Supplement 1): 1721.

https://doi.org/10.1182/blood-2023-191123

Published: 2023

Journal Articles

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

Abhishek Maiti, Naval Daver, Swami P. Iyer, David McCall, Satyen H Gohil, Javier Lopez Jimenez, Hayley Lane, Benjamin Kim, Kim-Hien Dao, Gary Patou, Sandip Panicker, Kelly Covert, Graham Carl Parry, Carl E Allen

Blood (2023) 142 (Supplement 1): 1162.

https://doi.org/10.1182/blood-2023-177795

Published: 2023

Journal Articles

Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience

Blood (2023) 142 (Supplement 1): 6327.

https://doi.org/10.1182/blood-2023-191096

Published: 2023

NARROW

Brentuximab Associated Guillain-Barré Syndrome (BV-GBS): Case Series and a Review of Pharmacovigilance FDA Adverse Reporting System (FAERS)

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Trial in Progress: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-Cop to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma - Crescendo

An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL

Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Preclinical Evaluation of T-Cell Prolymphocytic Leukemia Demonstrates Heterogeneous BCL2-Family Dependency That May be Effectively Targeted with Small Molecule Inhibitors

Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Developing Deep Learning Pipeline of Whole-Slide Images for Enhanced Diffuse Large B Cell Lymphoma (DLBCL) Subtyping and Outcome Prediction: Leveraging Self-Attention Transformer for Training and Inference

Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial

Differing Inflammatory Profiles and Survival Outcomes of Cytokine Storm Arising from CAR T-Cell Therapy, COVID and Malignancy-Associated HLH in Patients with Hematological Malignancies

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS): A Review of Pharmacovigilance

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma

Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only